INTRODUCTION: Cell-free DNA is suggested as a prognostic biomarker in metastatic castration-resistant prostate cancer. However, it remains unknown which parameter of cell-free DNA is correlated with the progression and prognosis of metastatic castration-resistant prostate cancer. CASE PRESENTATION: A 75-year-old man with newly diagnosed prostate cancer (serum prostate-specific antigen 4891 ng/mL, Gleason score 4 + 5 = 9, cT3bN1M1) was referred to our department. He first received sequential hormonal therapies and was consequently diagnosed metastatic castration-resistant prostate cancer 64 months after initial treatment. He underwent serial examinations of plasma cell-free DNA, including concentration, androgen receptor amplification, TP53 point mutation, and PTEN loss. Only the cell-free DNA concentration increased along with disease progression and declined after the administration of abiraterone and enzalutamide. CONCLUSION: This case presented that cell-free DNA concentration was possibly correlated with response to castration-resistant prostate cancer treatment and disease progression. Cell-free DNA concentration was proposed as a potential prognostic biomarker of metastatic castration-resistant prostate cancer.
INTRODUCTION: Cell-free DNA is suggested as a prognostic biomarker in metastatic castration-resistant prostate cancer. However, it remains unknown which parameter of cell-free DNA is correlated with the progression and prognosis of metastatic castration-resistant prostate cancer. CASE PRESENTATION: A 75-year-old man with newly diagnosed prostate cancer (serum prostate-specific antigen 4891 ng/mL, Gleason score 4 + 5 = 9, cT3bN1M1) was referred to our department. He first received sequential hormonal therapies and was consequently diagnosed metastatic castration-resistant prostate cancer 64 months after initial treatment. He underwent serial examinations of plasma cell-free DNA, including concentration, androgen receptor amplification, TP53 point mutation, and PTEN loss. Only the cell-free DNA concentration increased along with disease progression and declined after the administration of abiraterone and enzalutamide. CONCLUSION: This case presented that cell-free DNA concentration was possibly correlated with response to castration-resistant prostate cancer treatment and disease progression. Cell-free DNA concentration was proposed as a potential prognostic biomarker of metastatic castration-resistant prostate cancer.
Authors: Himisha Beltran; Alessandro Romanel; Vincenza Conteduca; Nicola Casiraghi; Michael Sigouros; Gian Marco Franceschini; Francesco Orlando; Tarcisio Fedrizzi; Sheng-Yu Ku; Emma Dann; Alicia Alonso; Juan Miguel Mosquera; Andrea Sboner; Jenny Xiang; Olivier Elemento; David M Nanus; Scott T Tagawa; Matteo Benelli; Francesca Demichelis Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: V Conteduca; D Wetterskog; M T A Sharabiani; E Grande; M P Fernandez-Perez; A Jayaram; S Salvi; D Castellano; A Romanel; C Lolli; V Casadio; G Gurioli; D Amadori; A Font; S Vazquez-Estevez; A González Del Alba; B Mellado; O Fernandez-Calvo; M J Méndez-Vidal; M A Climent; I Duran; E Gallardo; A Rodriguez; C Santander; M I Sáez; J Puente; D Gasi Tandefelt; A Wingate; D Dearnaley; F Demichelis; U De Giorgi; E Gonzalez-Billalabeitia; G Attard Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976